UCL Cancer Institute, Cancer Research UK and UCL Cancer Trials Centre, London, UK.
Ann Oncol. 2012 Sep;23 Suppl 10:x118-27. doi: 10.1093/annonc/mds315.
Treatment of ovarian cancer remains challenging despite the high complete response rate seen after maximal surgical debulking surgery and platinum-combination chemotherapy. as most patients will relapse and eventually succumb to ovarian cancer, new strategies are urgently required to improve survival. a platinum-taxane combination has been the cornerstone of treatment for >15 years. Better use of these drugs is being explored through scheduling studies, and dose-dense or intraperitoneal (IP) therapies. Further improvements in treatment will most likely come from the integration of optimal chemotherapy with one or more of the hundreds of molecular-targeted agents that could be active in ovarian cancer. The greatest experience has been with anti-angiogenic agents. Two large phase III trials in first-line ovarian cancer have demonstrated a positive effect of bevacizumab when administered concurrently with chemotherapy and then as a maintenance treatment. In this review, we discuss the existing treatments for ovarian cancer and highlight areas of recent progress.
尽管在最大程度的手术去瘤和铂类联合化疗后，完全缓解率很高，但卵巢癌的治疗仍然具有挑战性。由于大多数患者会复发并最终死于卵巢癌，因此迫切需要新的策略来提高生存率。铂类紫杉醇联合治疗已经成为治疗的基石超过 15 年。通过调度研究、剂量密集或腹腔内（IP）治疗正在探索更好地使用这些药物。通过将最佳化疗与一种或多种可能对卵巢癌有效的数百种分子靶向药物相结合，很可能会进一步改善治疗效果。最大的经验来自于抗血管生成药物。两项一线卵巢癌的大型 III 期临床试验表明，贝伐单抗与化疗同时给药，然后作为维持治疗，可产生积极效果。在这篇综述中，我们讨论了现有的卵巢癌治疗方法，并强调了最近的进展领域。
